PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of bioinformLink to Publisher's site
 
Bioinformation. 2013; 9(4): 174–181.
Published online 2013 February 21. doi:  10.6026/97320630009174
PMCID: PMC3602886

Resistome analysis of Mycobacterium tuberculosis: Identification of aminoglycoside 2'-Nacetyltransferase (AAC) as co-target for drug desigining

Abstract

The emergence of multidrug resistant tuberculosis (MDRTB) highlights the urgent need to understand the mechanisms of resistance to the drugs and to develop a new arena of therapeutics to treat the disease. Ethambutol, isonazid, pyrazinamide, rifampicin are first line of drugs against TB, whereas aminoglycoside, polypeptides, fluoroquinolone, ethionamide are important second line of bactericidal drugs used to treat MDRTB, and resistance to one or both of these drugs are defining characteristic of extensively drug resistant TB. We retrieved 1,221 resistant genes from Antibiotic Resistance Gene Database (ARDB), which are responsible for resistance against first and second line antibiotics used in treatment of Mycobacterium tuberculosis infection. From network analysis of these resistance genes, 53 genes were found to be common. Phylogenetic analysis shows that more than 60% of these genes code for acetyltransferase. Acetyltransferases detoxify antibiotics by acetylation, this mechanism plays central role in antibiotic resistance. Seven acetyltransferase (AT-1 to AT-7) were selected from phylogenetic analysis. Structural alignment shows that these acetyltransferases share common ancestral core, which can be used as a template for structure based drug designing. From STRING analysis it is found that acetyltransferase interact with 10 different proteins and it shows that, all these interaction were specific to M. tuberculosis. These results have important implications in designing new therapeutic strategies with acetyltransferase as lead co-target to combat against MDR as well as Extreme drug resistant (XDR) tuberculosis.

Abbreviations

AA - amino acid, AT - Acetyltransferase, AAC - Aminoglycoside 2'-N-acetyltransferase, XDR - Extreme drug-resistant, MDR - Multidrug-resistant, Mtb - Mycobacterium tuberculosis, TB - Tuberculosis.

Keywords: Antibiotic resistance, Mycobacterium tuberculosis, Acetyltransferase, Network analysis

Background

Tuberculosis (TB), a bacterial origin infectious disease caused by obligate human pathogen Mycobacterium tuberculosis (Mtb). TB as a single infectious disease is responsible for the leading cause of deaths in developing as well as developed countries. It is estimated that annually 2 million people are dying due to this treatable disease. According to World Health Organization (WHO) reports for the year 2010, 8.8 million incident cases of TB were estimated globally. The highest number of deaths was in the African region. Without treatment against TB, mortality and morbidity are high. Despite the overwhelming research going on to understand the pathogenesis of Mycobacterium tuberculosis, increasing drug resistance in pathogen requires development of new therapeutic and preventive strategies [1].

Co-infection with HIV has given new dimension to the TB epidemics. It has been reported that 1.1 million deaths among HIV-negative cases of TB and an additional 0.35 million deaths among people who were HIV-positive occurred [2, 3]. Major setback to the Global TB eradication program is the rise of Multidrug Resistant (MDR) and Extreme Drug Resistant (XDR) mutants of M. tuberculosis, which are resistant to the first line and second line of anti-tuberculosis drugs. Drug resistance can be defined as the temporary or permanent capacity of organisms and their progeny to remain viable or to multiply in the presence of the concentration of the drug that would normally destroy or inhibit cell growth [4]. Multi-drug resistant tuberculosis (MDR-TB) is a disease caused by strains of M. tuberculosis that are at least resistant to treatment with isonazid and rifampicin. Extensively drug-resistant tuberculosis (XDRTB) refers to disease caused by multidrug-resistant strains that are also resistant to treatment with any fluoroquinolone and any of the injectable drugs used in treatment with second-line anti-tuberculosis drugs (amikacin, capreomycin, and kanamycin) [4]. There are many factors like clinical, biological and socioeconomic which are responsible for the rise of drug resistance associated with Mtb infection [5, 6, 7].

The resistance acquired by pathogen may be due to plasmid, which carries different antibiotic resistance genes. The other MDR mechanisms are due to sequential accumulation of chromosomal mutations in different drug resistant genes that commonly occurs in case of MDR-TB and XDR-TB. Chromosomal mutations may be responsible for the different effect like reduced permeability, increased efflux, enzymatic inactivation, or alteration of drug target [8]. In light of this, it becomes necessary to search for the new targets to contain the TB epidemic globally. To counter the drug resistance in Mtb, global efforts are on to explore novel strategies for drug development and search for new therapeutic molecules as a drug target. Methods such as rotations of antibiotic combinations, improved medical surveillance to ensure proper patient compliance towards drug therapy are proving less useful compared to speed with which pathogen is becoming resistant to drugs. Identification of new targets that may be less prone to mutations, search for new chemical modulators for known molecular targets , use of virulence factors as targets and ‘phenotypic conversion’, which aims to inhibit the resistance mechanism employed by the bacterium [9, 10]. In this era of “Omics” where various databases are available, use of computational approaches to mine the possible therapeutic target seems much feasible requiring future experimental validation.

This study includes construction and analysis of molecular interaction networks, which provides a powerful means to understand the complexity of biological systems and to reveal hidden relationships between drugs, genes, proteins, and diseases. In recent years, several computational methodologies have been developed to predict and develop models to understand the complexity of diseases like tuberculosis [1115]. Analysis of genetic makeup will provide information about the crosstalk between different proteins, which can provide a new way to identify a potential targets. Here, we use wide-scale network and phylogenetic analysis of genes and proteins association to discover possible new target to combat against MDR-TB and XDR-TB. The network analyses reported here further help in identification of genes, which are activated in response to resistance against antibiotics. The complete methodology for this analysis is represented as flowchart (Figure 1). The study also identify some protein that could be explored for their use as drug ‘co-targets’.

Figure 1
Progression of experiments in this study: A flowchart illustrating the progression of experiments in this study. Different aspects indicated in this are Database construction, curation of the resistance proteins, identification of common genes by network ...

Methodology

Data collection and Network analysis:

Genes and Proteins encoding for the antibiotic resistance against first line antibiotics, like, aminoglycoside, ethambutol, isonazid, pyrazinamide, flouroquinoles and rifampin were retrieved from the Antibiotic Resistance Gene Database [16] and collected in form of subset of main database. We analyzed and compared the genes for their screening and inclusion criteria of interactions. The interaction network for these genes were build and visualized by Cytoscape v2.8.2 software [17, 18]. In order to map the common genes in the interaction network, we used Entrez Gene ID as the unique identifier for genes.

Sequence analysis and Phylogenetic analysis:

The protein sequences that are found to be common through network analysis from M. tuberculosis H37Rv and other Mycobacterium species were retrieved from NCBI (http://www.ncbi.nlm.nih.gov). Similarity in the selected sequences were evaluated by Blastp [19]. The multiple alignments and phylogenetic analysis of selected sequences were done using MEGA5 software [20, 21]. Furthermore, analysis of the conserved motif in common 53 proteins aa sequence was performed by MEME online server, which use comparative analysis mode for finding conserved motifs [2224].

Protein Interaction Network:

A proteome-scale interaction network of proteins in M. tuberculosis with aminoglycoside 2'-N-aminoglycoside 2'-Nacetyltransferase AAC was derived from the STRING database [25, 26], using “High-confidence” and “Medium-confidence” data. Coexpression and Occurrence analysis for this protein was obtained from STRING database. Blastp analysis [27] against a human protein database was done to validate that this particular protein not share any homology with human proteins.

Homology modeling and structural comparison:

Seven different Aminoglycoside 2'-N-acetyltransferase (AAC) (AT-1 to -7) from different clads were selected and amino acid sequence analysis was done by performing a multiple sequence alignment using ClustalX and also conserved sequences and motifs were identified using PSI-BLAST search [28, 29] and Pfam database [30]. Amino acid sequence of selected aminoglycoside 2'-N-acetyltransferase (AACs) of M. tuberculosis was aligned with bovine trypsin sequence (PDB ID: 1M4D; Aminoglycoside 2'-N-aminoglycoside 2'-N-acetyltransferase (AAC) from Mycobacterium tuberculosis in complex with coenzyme A and aminoglycoside substrates; Resolution= 1.8A°). The 3D models were generated using the MODELLER package (version 9.10) [31]. All the models were energy minimized using a conjugate gradient algorithm and short MD simulations, as part of the MODELLER protocol in order to refine the side chain orientations. 50 models were generated for each sequence, which were rated according to the GA341 and DOPE scoring functions [32]. The structures were analyzed using PyMol software [33, 34] and superimposed using TM align server (http://zhanglab.ccmb.med.umich.edu/TMalign/) [35]. The models were also analyzed for oligomeric states using SCORER 2.0 program [36, 37]. The 3-D structures of predicted models were validated with the programs PROCHECK and ProSA analysis. These programs generate Ramchandran plots of the amino acid residues in the allowed region and consider the overall G -factors to give scores for predicting model quality.

Result

All antibiotics share common genetic makeup for resistance:

Network analysis shows that selected 1221 resistant genes form 1220 interactions with six nodes, which represent each individual antibiotic (Figure 2). Fifty-three genes were found to be common among selected first line and second line antibiotics resistant genes, whereas aminoglycosides and Flouroquinoles share 41 common resistance genes. These common 53 genes encode for mechanisms of destruction and detoxification of antibiotics. Out of common 53 genes, 28 codes for aminoglycoside N-acetyltransferase, this modifies aminoglycosides by acetylation. Remaining genes were encoded for a product like Class A beta-lactamase (Q5951; This Enzyme breaks the beta-lactam antibiotic ring open and deactivates the molecule's antibacterial properties), tetracycline Efflux pump (AAB84282, YP_889433), and Sulfonamideresistant dihydropteroate synthase (Q49184). Another major group of genes (21 genes) produces pentapeptide as functional product, which protect DNA gyrases from the inhibition of quinolones.

Figure 2
Illustration of the gene network: Hexagonal node represents antibiotics (Pink in colour) and circular nodes (Yellow) correspond to the individual genes in the network while the edge (Grey) indicate interactions between them. Enlarged view of network show ...

Acetyltransferases shows divergent evolution:

Outcome of multiple alignments (Figure 3) gives that, 53 amino acid sequences of common genes from Mycobacterium tuberculosis and related species of M. tuberculosis shares 90% of sequence similarity. Phylogenetic analysis shows that out of these 53 genes, 28 genes which codes for Aminoglycoside 2'-Nacetyltransferase (AAC) activity cluster together. This acetyltransferase cluster is subdivided in 7 different clad, signifies for small sequence variation in related sequences. All results from multiple alignment and phylogenetic analysis show that acetyltransferases in Mycobacterium tuberculosis were evolved divergently from ancestral component.

Figure 3
Phylogenetic analysis of common genes: Phylogenetic tree comprises of 53 common genes which were identified by network analysis. Shaded region shows sequences which code for acetyltransferase activity.

M. tuberculosis aminoglycoside 2'-N-acetyltransferase (AAC) shows association with Non-Housekeeping genes:

From STRING database, proteome-scale interaction network of proteins in M. tuberculosis H37Rv was derived Table 1 (see supplementary material). This database takes account of interactions from published literature describing experimentally studied interactions as well as those from genome analysis using several well established methods such as domain fusion, phylogenetic profiling and gene neighborhood concepts. This network comprises of different types of interactions such as Coexpression, co-existence and common neighborhood (or domain fusion) of query protein. In our study, we found that aminoglycoside 2'-N-acetyltransferase (AAC) form M. tuberculosis are interacting with 10 different proteins as summarized in (Figure 4). Out of these 10 proteins, 5 proteins MT3587, MT2804, MT027, mmpS5 and MT0276 codes for hypothetical proteins, whereas remaining proteins are also of specialized function. Prediction of Coexpression shows that only three proteins pra, MT0185 and mmpS5 are associated with each other with medium confidence value (0.4) and also this association is specific for M. tuberculosis H37Rv (Figure 4). From the STRING database Neighborhood analysis we can predict that aminoglycoside 2'-N-acetyltransferase AAC (Rv0262c) is closely associated with two hypothetical proteins Rv0264c and Rv0263c. Blastp analysis against Homo sapiens protein database show that aminoglycoside 2'-Nacetyltransferase AAC doesn't share any homology with human protein.

Figure 4
Illustration of the AAC protein interaction from STRING database: A) Network of protein-protein Interaction of AAC in M. tuberculosis; B) Heat map showing degree of Coexpression in AAC interacting proteins; C) Prediction of Co-occurrence of ACC (Rv262c) ...

All acetyltransferase shares a common ancestral core:

Predicted models of aminoglycoside 2'-N-acetyltransferases show common structure despite of their sequence divergence. According to Ramchandran pot analysis using PROCHECK, all predicted models have 98% of aa in favored and allowed region (Figure 5A). SCORER 2.0 analysis shows that all protein were predicted to form dimer. Each structure is composed of two interconnected beta sheets and four alpha helices. Strands β1-4 form relatively flat antiparallel β sheet, while helices α1, α2, α3 lie against the flat surface of β sheet, whereas strands β5-10 and portion of β3, β4 forms the open barrel with mixed topology. Helix α4 lies against the outer surface of this barrel. This allstructural features were remained common for all selected acetyltransferase, which leads to conclusion that all seven acetyltransferase share common ancestral structural core.

Figure 5
Structural comparison between acetyltransferase: Conservation in structure between aminoglycoside acetyltransferase in M. tuberculosis. Common region from all seven structures is highlighted as ancestral core, which is shown at the centre; B) Mapping ...

Validation of acetyltransferase as co-target for Antituberculosis drugs:

PyMol and Accelerys Discovery Studio Visualizer 3.0 (http://accelrys.com/) were used for structural analysis. The mapping of a conserved motif obtained from MEME analysis, on predicted models of acetyltransferases (Supplementary Figure 1) shows that the binding pocket of this particular class of protein is highly conserved in Mtb and related species (Figure 5B). Blastp analysis shown that (AT) from M. tuberculosis were unrelated to any class of human protein Table 1 (see Supplementary material). This all features makes acetyltransferases as potential co-target for existing and new developing class of drugs.

Discussion

Complexity in “Omics” of M. tuberculosis and also the emergence of MDR and XDR strains gives it potential to be one of most lethal infectious pathogen. Multidisciplinary and multifaceted approaches can serve as better mean to solve the complexity of this pathogen. During the course of time, different terms like drugome, reactome, and pocketome had developed in the context of tuberculosis study. Here we are using term ‘Resistome' that signifies interaction of genes, proteins and metabolites, to evoke resistance of the organism against drugs and antibiotics. There are few reports, which show use integrative approach to study the complexity in the resistance mechanism of M. tuberculosis [11, 19, 26]. Computational analysis in terms of network analysis, statistical analysis and other way provides a very effective tool to handle very large and complex data and also to produce some concluding remarks about the complexity of Mtb. Network and interaction analysis is a very useful tool to study genome wide and proteome wide interaction analysis in M. tuberculosis. In 2008, Chandra et al. had shown the proteome wide interaction in Mtb. Here in this report we had used network analysis to make a systematic cluster of 1, 221 genes which are responsible for antibiotic resistance against the first and second line of drugs. Our analysis also provides information about genes found to be common in resistance mechanism against different antibiotics. Fifty-three genes were found to be common for aminoglycosides, flouroquinolones, rifampicin, isonazid, ethambutol, and pyrazinamide, whereas 41 genes were found to be overlapping in flouroquinolones and aminoglycosides resistance. According to the ARDB functional annotation, out of 53 common genes 28 gene codes for acetyltransferase AT, 21 codes for pentapeptide that is responsible for resistance against flouroquinolones. From this analysis AT was found to be a major enzymatic mechanism of resistance against all first and second line drugs, which make this molecule as a potential target as a Co-target for existing and new developing drug strategies.

Phylogenetic and structural analysis shows that all the candidates of selected AAC shares common ancestor. Structural analysis of representative AAC from each clad of the phylogenic tree provides very important informatics about the basic ancestral core of all different AAC from M. tuberculosis and related species. From SCORER 2.0, analysis all AAC was predicted to form dimer and MEME analysis shows that region which is involved in dimer formation is conserved for all structures. Another important result from MEME analysis shows that region which is responsible for ligand for in AAC is also conserved in all selected AAC. Development of AAC as Co target also requires some pre requisite like it should not show homology with human proteins, and it should be involved in housekeeping functions in M. tuberculosis. Blastp search against the human proteome shows that AAC is not homologous to any human protein, so it is concluded that AAC is specific for M. tuberculosis. From the STRING database analysis it is found that AAC can probably interact with 10 different proteins from M. tuberculosis. This AAC protein interaction comprises of 5 hypothetical protein (Rv3483c, Rv2735c, Rv0264c, Rv0677c and Rv0263c), 2 membrane protein (Rv0403c, Rv0200), proline-rich antigen (Rv1078), MCE associated protein (Rv0177), and mce associated transmembrane protein (Rv0176). Coexpression analysis of these interacting proteins shows that Rv1078 and Rv0176 found to be Co-expressing, whereas AAC (Rv0262c) found to be coexisting with Rv0263c and Rv0264c. This Coexpression and Coexistence analysis is found to be specific for M. tuberculosis, and it shows that AAC is not involved in or interacting with the housekeeping function of M. tuberculosis. This all data will be useful for exploiting AAC as Co-target.

Emergence of drug resistance in M. tuberculosis leads to put efforts aimed at identifying new potent broad-spectrum drugs/antibiotics, but along with this, it is necessary to take account of drug resistance mechanism and the way to overcome this. Development of drug targeting co-target like Aminoglycosides transferases will be effective in enhancing efficacy of existing anti mycobacterial regime and it will provide additional strength for newly developing drugs.

Conclusion

Network analysis of different antibiotic resistance gene in M. tuberculosis has provided the platform for identifications of cotargets. Further structural characterization and analysis using different tools like structural superimposition and binding site predictions might be useful for targeting these co-targets. Furthermore, it is also useful to develop several inhibitor molecules against these co-targets in process of antituberculosis drug development.

Supplementary material

Data 1:

Acknowledgments

RSJ and MDJ acknowledge CSIR for the research fellowships. MSS is grateful to acknowledge the financial support provided by the Department of Biotechnology (DBT), Government of India, New Delhi. The authors are grateful to acknowledge Council of Scientific and Industrial Research, New Delhi, India for their financial support to this work. The authors are grateful to acknowledge Dr. Rajesh Kumar Singh, Gennova Biopharmceticals Ltd., Pune, India and Dr. Milind S. Patole from NCCS, Pune 411007, MS, India for their critical comments. The authors have declared no conflict of interest.

Footnotes

Citation:Joshi et al, Bioinformation 9(4): 174-181 (2013)

References

1. Glickman MS, Jacobs WR Jr. Cell. 2001;104:477. [PubMed]
2. Global tuberculosis control: WHO report 2011. 2011
3. Kim HR, et al. Clin Infect Dis. 2007;45:1290. [PubMed]
4. Singla N, et al. Indian J Tuberc. 2009;56:206. [PubMed]
5. Crino PB, et al. N Engl J Med. 2006;355:1345. [PubMed]
6. Zhang Y, Yew WW. Int J Tuberc Lung Dis. 2009;13:1320. [PubMed]
7. Alekshun MN, Levy SB. Cell. 2007;128:1037. [PubMed]
8. Kant S, et al. Biosci Trends. 2010;4:48. [PubMed]
9. Riccardi G, et al. Future Microbiol. 2009;4:597. [PubMed]
10. Donald PR, Van Helden PD. N Engl J Med. 2009;360:2393. [PubMed]
11. Raman K, Chandra N. BMC Microbiol. 2008;8:234. [PMC free article] [PubMed]
12. Kinnings SL, et al. PLoS Comput Biol. 2010;6:e1000976. [PMC free article] [PubMed]
13. Ahmed N, Hasnain SE. Tuberculosis (Edinb) 2011;91:407. [PubMed]
14. Mazandu GK, Mulder NJ. Infect Genet Evol. 2012;12:922. [PubMed]
15. Padiadpu, et al. Syst Synth Biol. 2010;4:311. [PMC free article] [PubMed]
16. Liu B, Pop M. Nucleic Acids Res. 2009;37:D443. [PMC free article] [PubMed]
17. Gottlieb A, et al. Bioinformatics. 2011;27:3325. [PubMed]
18. Cline MS. Nat Protoc. 2007;2:2366. [PubMed]
19. Kumar D, et al. Cell. 2010;140:731. [PubMed]
20. Tamura K, et al. Mol Biol Evol. 2011;28:2731. [PMC free article] [PubMed]
21. Chang G, et al. Science. 1998;282:2220. [PubMed]
22. Blekas K, et al. Bioinformatics. 2003;19:607. [PubMed]
23. Joon M, et al. BMC Microbiol. 2010;10:128. [PMC free article] [PubMed]
24. Kendall SL, et al. Microbiology. 2010;156:1362. [PMC free article] [PubMed]
25. von Mering C, et al. Nucleic Acids Res. 2007;35:358. [PubMed]
26. Raman K, et al. BMC Syst Biol. 2008;2:109. [PMC free article] [PubMed]
27. Sharma P, et al. Proteome Sci. 2010;8:59. [PMC free article] [PubMed]
28. Altschul SF, et al. Nucleic Acids Res. 1997;17:3389. [PMC free article] [PubMed]
29. Larkin, et al. Bioinformatics. 2007;23:2947. [PubMed]
30. Bateman A. Nucleic Acids Res. 2004;32:D138. [PMC free article] [PubMed]
31. Sali A, Blundell TL. J Mol Biol. 1993;234:779. [PubMed]
32. Shen MY, Sali A. Protein Sci. 2006;15:2507. [PubMed]
33. Yam KC, et al. PLoS Pathog. 2009;5:e1000344. [PMC free article] [PubMed]
34. Guex N, Peitsch MC. Electrophoresis. 1997;18:2714. [PubMed]
35. Armstrong CT, et al. Bioinformatics. 2011;27:1908. [PubMed]
36. Ramesh KV, et al. J Biomol Struct Dyn. 2007;24:393. [PubMed]
37. Wiederstein M, Sippl MJ. Nucleic Acids Res. 2007;35:W407. [PMC free article] [PubMed]

Articles from Bioinformation are provided here courtesy of Biomedical Informatics Publishing Group